Chinook Therapeutics downgraded by Wedbush with a new price target
$KDNY
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush downgraded Chinook Therapeutics from Outperform to Neutral and set a new price target of $42.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $42.00 | Outperform → Neutral | Wedbush |
| 3/6/2023 | $41.00 | Overweight | Piper Sandler |
| 3/1/2023 | $43.00 | Buy | Guggenheim |
| 12/5/2022 | $30.00 | Overweight | Wells Fargo |
| 6/28/2022 | $30.00 | Buy | Stifel |
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu
SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer. "We are pleased to welcome Andrew to Chinook as we prepare for a year of important milestones for our atrasentan and BION-1301 programs," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Andrew is an accomplished industry leader with more than 20 years of global biopharmaceutical experience and a proven track record of building commercial strategies and executing n